8octobre

[News] - Low Dose Interleukin-2 for treating type 1 diabetes

mardi, octobre 8 (00:00), 2013
A team of researchers coordinated by Professor Klatzmann has defined a well-tolerated and immunologically effective dose range of IL2 for application to type 1 diabetes therapy and prevention. Published in Lancet Diabetes and Endocrinology, this work opens new therapeutic perspectives for the treatment of autoimmune diseases.

A. Hartemann et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology, Early Online Publication, 8 October 2013 - doi:10.1016/S2213-8587(13)70113-X​